BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27

• 

  IgA nephropathy

  Otsuka Sees ‘Impressive’ Proteinuria Reduction in Phase III IgAN Trial

  Otsuka’s investigational antibody sibeprenlimab approximately halved levels of this key biomarker in patients with immunoglobulin A nephropathy.

  June 6, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Regulatory

  RFK Jr. Joins Deputies in Voicing Support for Regulatory Flexibility for Cell and Gene Therapies

  In a roundtable event on Thursday, HHS Secretary Robert F. Kennedy Jr. said his office will work to eliminate barriers that keep cell and gene therapies from the market.

  June 6, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Radiopharmaceuticals

  Perspective Therapeutics Brings Energy to the Radiopharma World

  The Seattle-based company came to ASCO25 with new data on its neuroendocrine tumor–treating lead therapy, with big vibes and speedy speech.

  June 6, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• 

  ALS

  Corcept Claims Survival Benefit in ALS Despite Missed Endpoint

  Analysts at Truist Securities called the mid-stage data a “mixed bag,” also flagging gastrointestinal adverse events. However, the readout is unlikely to be “incremental” to Corcept’s overall stock narrative.

  June 6, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Editorial

  Desperate Times, Desperate Measures? RFK’s Vaccine Campaign Only Breeds More Distrust

  Vaccine skepticism is at an all-time high in the U.S., and HHS Secretary Robert F. Kennedy Jr. is making some drastic moves in the name of reversing that trend. But misinformation and inconsistencies within the country’s healthcare agencies highlight problems with his approach.

  June 6, 2025

   · 

  8 min read

   · 

  Jef Akst
• 

  GLP-1

  EU Regulators Confirm Rare Vision Loss Risk for Novo’s Semaglutide

  Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include the “very rare” risk of non-arteritic anterior ischemic optic neuropathy.

  June 6, 2025

   · 

  1 min read

   · 

  Annalee Armstrong
• Press Releases

  QureBio Ltd. Completes Nearly CNY 100 Million Series C1 Financing Led by Efung Capital, accelerating clinical progress in global competition for core pipelines

  June 6, 2025

   · 

  5 min read
• Press Releases

  Penumbra Introduces the Ruby® XL System - the Longest, Largest, and Softest Coil on the Market for Vascular Embolization

  June 6, 2025

   · 

  5 min read
• Press Releases

  Centinel Spine® Continues to Innovate in Lumbar Total Disc Replacement through the Release of New prodisc® L Instrumentation

  June 6, 2025

   · 

  5 min read
• Press Releases

  GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

  June 6, 2025

   · 

  10 min read